Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Sun Pharma Announces U.S. FDA Approval of ILUMYA™

Posted On: 2018-03-21 07:07:19

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that the U.S. Food and Drug Administration (FDA) has approved ILUMYA™ (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMYA™ selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA™ is administered at a dose of 100 mg by subcutaneous injection every 12 weeks, after the completion of initial doses at weeks 0 and 4. ILUMYA™ is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

"With the approval of ILUMYA™ and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis," said Abhay Gandhi, President and Chief Executive Officer, North America, Sun Pharma. "We are committed to working with all relevant stakeholders to make ILUMYA™ available to appropriate people with plaque psoriasis."

The FDA approval of ILUMYA™ for the treatment of adults with moderate-to-severe plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program. In the two multicenter, randomized, double-blind, placebo-controlled trials (reSURFACE 1 and reSURFACE 2), 926 adult patients were treated with ILUMYA™ (N=616) or placebo (N=310). Results from these studies were published in The Lancet in July 2017, with primary endpoints presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress.

Both Phase-3 studies met the primary efficacy endpoints, demonstrating significant clinical improvement with ILUMYA™ 100 mg compared to placebo when measured by at least 75 percent of skin clearance (Psoriasis Area Sensitivity Index or PASI 75) and Physician's Global Assessment (PGA) score of "clear" or "minimal" at week 12 after two doses.

Of the patients in the reSURFACE 1 study 74 percent (229 patients) achieved 75 percent skin clearance at week 28 after three doses, and 84 percent of patients who continued receiving ILUMYA™ 100 mg maintained PASI 75 at week 64 compared to 22 percent of patients who were re-randomized to placebo. In addition, 69 percent of the patients receiving ILUMYA™ 100 mg who had a PGA score of "clear" or "minimal" at week 28 maintained this response at week 64 compared to 14 percent of patients who were re-randomized to placebo.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.504.7 as compared to the previous close of Rs. 508.85. The total number of shares traded during the day was 409209 in over 3190 trades.

The stock hit an intraday high of Rs. 515.8 and intraday low of 502.8. The net turnover during the day was Rs. 208634257.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

IndusInd Bank Q4 net profit climbs to Rs. 953.09 crores
L3 MAS Goes Live on Ramco Aviation Suite
Welspun Corp Ltd bags contract for supply of 114 K MTs of large diameter pipes
MCX Partners with Northern India Textiles Mills' Association
Honeywell Automation India Limited announces expansion of its manufacturing facility in Pune
Bharat Bijlee Ltd commissions facility for Magnet Technology Machines
Indusind Bank Ltd recommends dividend of Rs. 7.50
NACL Industries Ltd enters into agreement with BioWorks Inc.
Menon Bearings Ltd Board to consider final dividend, FY18 results on May 3, 2018
Wabag secures order under Namami Gange Scheme worth Rs. 253 crores
Carnation Industries Ltd Board to consider Dividend on May 25, 2018
EIH Associated Hotels Ltd to close Trident Udaipur partially for renovation
Reliance Infrastructure bags EPC contract from Rail Vikas Nigam Limited for railway project worth Rs 774 crore
Thomas Cook India Launches 'The Grand Forex Festival' to catalyse demand
Apollo Tyres Ltd Board to consider FY18 results on May 10, 2018
Vascon Engineers Ltd receives new work order for Rs. 119 crores
Tejnaksh Healthcare Ltd Fixes Apr 28, 2018 as Record Date for Bonus Shares
Sandhar Technologies Ltd calls for Board Meeting On May 26, 2018
Ultra Tech sets new benchmarks in commissioning of Greenfield Factory in South-West MP
R Systems International Limited revised Book Closure for 24th AGM
Mastek Ltd Fixes Book Closure for Final Dividend & 36th AGM
Parag Milk Foods Ltd to acquire Danone Foods' facility at Rai, Sonipat, Haryana
Trigyn Technologies Inc. awarded IT Professional Servies Contract by Maryland Health Benefit Exchange
Archit Organosys Ltd calls for Board Meeting on Apr 23, 2018
Reliance Capital Ltd Board to announce FY18 results, dividend on Apr 26, 2018
Essel Propack Ltd Board to approve final dividend, FY18 results on Apr 26, 2018
Indian Energy Exchange Ltd to consider FY18 results on Apr 26, 2018
TI Financial Holdings Ltd to announce FY18 results on May 10, 2018
Dewan Housing Finance Corporation Ltd Board to consider FY18 results & Final Dividend on April 30, 2018
BW Businessworld SME Growth Leadership award for Trigyn Technologies Ltd
NMDC Ltd revises iron ore price from Apr 18, 2018
Hexaware Technologies Ltd Board to consider Q1 results, interim dividend on May 3, 2018
G E Shipping takes delivery of Secondhand Very Large Gas Carrier
Trigyn Technologies Inc. awarded Technology Support Staffing contract by Baltimore County Public Schools
Lemon Tree Hotels strengthens presence in Uttarakhand
Meera Industries Ltd to consider final dividend, FY18 results on Apr 25, 2018
Timex Group India Ltd announces resignation of Mr. Colin Davis Arsenault
SIL Investments Ltd Board to consider Dividend on May 8, 2018
Domino's Pizza's assurance to its Customers - We Use Real Cheese
Dhanlaxmi Bank Ltd to announce Q4, FY18 results on May 15, 2018
Infibeam Incorporation Ltd bags contract from NSDC
Kirloskar Pneumatic Company Ltd Board to consider Dividend on Apr 26, 2018
Container Corporation of India Ltd Board to consider Sub-division of Equity Shares
Pecos Hotels and Pubs Ltd announces temporary closure of the units for renovation
Navkar Builders Ltd approves appointment of additional director
Trigyn Technologies Inc. awarded IT Professional Services contract by Anne Arundel County
SeQuent Scientific announces acquisition of Bremer Pharma in Germany
Fortis Healthcare receives unsolicited bid from Fosun Health Holdings Ltd
ACC Ltd Q1 net profit rises to Rs. 250.39 crores
Mindtree Ltd Q4 consolidated PAT jumps to Rs. 182.2 crores


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018